AR and neoplasm: Subsequent rescue experiments demonstrated that KIF15 overexpression reduced the anti-tumor efficacy of ATR-I against AR+ and AR− CRPC cells, indicating that ATR-I suppressed the CRPC progression through targeting KIF15.